Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Consensus Rating of “Buy” by Brokerages

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) has received a consensus rating of “Buy” from the nine analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $35.71.

DAWN has been the subject of several research analyst reports. TD Cowen upgraded Day One Biopharmaceuticals to a “strong-buy” rating in a research note on Monday, November 4th. JPMorgan Chase & Co. reduced their price objective on shares of Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. Needham & Company LLC reissued a “buy” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday, October 31st. Finally, Bank of America upgraded Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and lifted their price target for the stock from $11.00 to $24.00 in a research note on Thursday, August 1st.

Insider Transactions at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 11,245 shares of the business’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $16.03, for a total transaction of $180,257.35. Following the completion of the transaction, the insider now directly owns 1,085,790 shares of the company’s stock, valued at $17,405,213.70. The trade was a 1.03 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last ninety days, insiders have sold 51,745 shares of company stock worth $775,867. 8.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Hedge funds have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. raised its stake in Day One Biopharmaceuticals by 38.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock valued at $51,000 after acquiring an additional 1,002 shares in the last quarter. SteelPeak Wealth LLC increased its holdings in shares of Day One Biopharmaceuticals by 9.8% during the third quarter. SteelPeak Wealth LLC now owns 17,400 shares of the company’s stock valued at $242,000 after purchasing an additional 1,550 shares during the period. Handelsbanken Fonder AB raised its stake in shares of Day One Biopharmaceuticals by 16.9% during the third quarter. Handelsbanken Fonder AB now owns 27,000 shares of the company’s stock valued at $376,000 after purchasing an additional 3,900 shares in the last quarter. Hennion & Walsh Asset Management Inc. lifted its holdings in Day One Biopharmaceuticals by 8.6% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 64,359 shares of the company’s stock worth $887,000 after purchasing an additional 5,070 shares during the period. Finally, Martingale Asset Management L P grew its position in Day One Biopharmaceuticals by 9.6% in the 3rd quarter. Martingale Asset Management L P now owns 71,304 shares of the company’s stock valued at $993,000 after buying an additional 6,219 shares in the last quarter. Institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Price Performance

Shares of DAWN stock opened at $13.72 on Thursday. The company’s fifty day moving average price is $14.35 and its two-hundred day moving average price is $14.18. The firm has a market capitalization of $1.38 billion, a P/E ratio of -13.32 and a beta of -1.51. Day One Biopharmaceuticals has a 12 month low of $11.30 and a 12 month high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its quarterly earnings results on Wednesday, October 30th. The company reported $0.38 EPS for the quarter, topping the consensus estimate of ($0.20) by $0.58. The business had revenue of $93.76 million during the quarter, compared to analyst estimates of $15.05 million. During the same quarter last year, the firm posted ($0.54) EPS. On average, sell-side analysts anticipate that Day One Biopharmaceuticals will post -0.88 EPS for the current year.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.